Merck, known as MSD outside the United States and Canada, yesterday announced results from its pivotal phase 3 KEYNOTE-564 trial evaluating Keytruda, its anti-PD-1 therapy.
The trial met its primary endpoint of disease-free survival (DFS) for the potential adjuvant treatment of patients with renal cell carcinoma (RCC) following the surgical removal of a kidney or following nephrectomy and resection of metastatic lesions.
The interim analysis was conducted by an independent Data Monitoring Committee, and Keytruda showed significant and meaningfully improvement compared with placebo in DFS.
Merck’s press release stated: ‘The trial will continue to evaluate overall survival (OS), a key secondary endpoint. The safety profile of Keytruda in this trial was consistent with that observed in previously reported studies.’
The press release added that results will be presented at an upcoming medical meeting and will be submitted to regulatory authorities.
Read more: http://www.pmlive.com/pharma_news/keytruda_shows_significant_and_meaningfully_improvement_in_kidney_cancer_1366614